Understanding HFO-1234ze and HFA-152a: A Formulator's Comparison Guide

Release 05th February 2026

The Urgency of Propellant Transition

The 2025 HFC phasedown regulations have created an immediate challenge for pharmaceutical formulators developing pressurised metered dose inhalers (pMDIs). As traditional HFC-134a faces restricted availability, development teams must evaluate low-global warming potential (GWP) alternatives—but the two leading candidates, HFO-1234ze and HFA-152a, present fundamentally different formulation profiles. This isn’t a simple substitution exercise. Each propellant demands distinct approaches to API solubility, excipient compatibility, and device integration. With regulatory deadlines approaching and reformulation timelines extending 18-24 months, the propellant selection you make today will determine whether your product reaches patients on schedule. This guide compares the practical formulation considerations that matter most to development teams navigating this transition.

What Is HFO-1234ze?

HFO-1234ze (trans-1,3,3,3-tetrafluoropropene) represents the hydrofluoroolefin class of propellants specifically developed as an environmentally sustainable alternative to traditional HFCs. With a GWP of less than 1—comparable to carbon dioxide—HFO-1234ze addresses climate concerns whilst maintaining pharmaceutical-grade purity standards required for inhalation products.

Physical and Chemical Properties

HFO-1234ze exhibits a vapour pressure of approximately 4.7 bar at 20°C, notably lower than HFC-134a’s 5.7 bar. This difference affects valve design, actuator force requirements, and ultimately the aerosol plume characteristics your patients will experience. The propellant’s density (1.16 g/mL at 25°C) influences suspension formulation behaviour and particle settling rates during storage.

From a formulation perspective, HFO-1234ze’s polarity differs significantly from HFC-134a, which directly impacts API solubility. According to studies published in the International Journal of Pharmaceutics, HFO-1234ze generally demonstrates lower solvating capacity for many common respiratory APIs compared to HFC-134a, though this varies considerably by molecular structure (Stein et al., 2020). For suspension formulations, this reduced solubility can actually prove advantageous by minimising valve deposition and maintaining dose consistency.

Regulatory Status and Safety Profile

HFO-1234ze carries an A2L flammability classification under ASHRAE Standard 34, indicating low toxicity and low flammability under standard conditions. This classification requires specific handling protocols during manufacturing but remains acceptable for pharmaceutical applications. Both the FDA and EMA have provided pathways for HFO-1234ze-based pMDI approvals, with several products already granted marketing authorisation.

The propellant’s environmental credentials extend beyond GWP. Its atmospheric lifetime of approximately 16 days means minimal long-term accumulation, addressing both climate and ozone depletion concerns that drove the original CFC phaseout.

Formulation Advantages

For development teams, HFO-1234ze offers several practical benefits:

• Reduced valve deposition due to lower API solubility in many cases
• Improved dose consistency over product lifetime in suspension formulations
• Compatibility with existing valve technologies with appropriate material selection
• Lower GWP than any other pharmaceutical propellant currently available
• Established regulatory pathway with precedent approvals in major markets

However, these advantages come with formulation complexity that requires specialised expertise to navigate effectively.

What Is HFA-152a?

HFA-152a (1,1-difluoroethane) has been investigated as a pharmaceutical propellant for over two decades, though commercial adoption has remained limited compared to HFC-134a. With a GWP of 138—significantly lower than HFC-134a’s 1,430 but higher than HFO-1234ze—it represents a pragmatic environmental improvement whilst offering distinct formulation characteristics.

Physical and Chemical Properties

HFA-152a demonstrates a vapour pressure of approximately 5.0 bar at 20°C, positioning it between HFO-1234ze and HFC-134a. This intermediate vapour pressure can facilitate device transition strategies, potentially allowing reformulation with minimal valve and actuator modifications. The propellant’s density (0.90 g/mL at 25°C) differs notably from both HFC-134a and HFO-1234ze, affecting suspension stability calculations and formulation density matching requirements.

The solvating properties of HFA-152a more closely resemble HFC-134a than those of HFO-1234ze, which can simplify reformulation programmes for APIs with established solubility profiles. Research in Respiratory Drug Delivery conferences has documented that many small molecule bronchodilators exhibit comparable solubility in HFA-152a and HFC-134a, though this must be verified for each specific API and excipient combination (Smyth et al., 2019).

Regulatory Status and Safety Profile

HFA-152a carries an A2 flammability classification, indicating higher flammability potential than HFO-1234ze’s A2L rating. This classification has historically created regulatory hesitation and requires enhanced safety protocols throughout manufacturing, storage, and distribution. Whilst technically feasible for pharmaceutical use, the flammability profile demands rigorous risk assessment and mitigation strategies.

The propellant has received regulatory approval for specific applications in certain markets, though adoption has been constrained by both flammability concerns and the subsequent development of lower-GWP alternatives. Regulatory agencies continue to evaluate HFA-152a submissions on a case-by-case basis, with particular scrutiny of manufacturing safety protocols.

Formulation Advantages

For specific development contexts, HFA-152a presents compelling attributes:

• Similar solvating properties to HFC-134a for many APIs
• Potential for simplified reformulation from existing HFC-134a products
• Intermediate vapour pressure facilitating device design continuity
• Lower cost compared to HFO-1234ze in current market conditions
• Established analytical methods adapted from HFC-134a programmes

Formulation teams must weigh these practical advantages against flammability management requirements and potential regulatory complexity.

Head-to-Head Comparison

The following table compares critical parameters that influence formulation development decisions:

Parameter	HFO-1234ze	HFA-152a	Formulation Impact
Global Warming Potential	<1	138	Regulatory preference increasingly favours HFO-1234ze; HFA-152a acceptable but less future-proof
Vapour Pressure (20°C)	4.7 bar	5.0 bar	HFA-152a’s higher pressure may simplify device transfer; both require valve optimisation
Density (25°C)	1.16 g/mL	0.90 g/mL	Significant difference affects suspension formulation and density matching strategies
Flammability Classification	A2L (low flammability)	A2 (flammable)	HFA-152a requires enhanced safety protocols; impacts manufacturing complexity and cost
API Solubility Profile	Generally lower than HFC-134a	Similar to HFC-134a	HFO-1234ze may require formulation optimisation; HFA-152a potentially simplifies reformulation
Regulatory Pathway	Well-established in EU/US	Case-by-case evaluation	HFO-1234ze has clearer regulatory precedent; HFA-152a faces additional scrutiny
Material Compatibility	Requires validation	Similar to HFC-134a	Both require compatibility testing; HFA-152a may leverage existing data

These technical differences fundamentally shape development strategy, timeline, and risk profile. Our experience across multiple low-GWP formulation programmes demonstrates that propellant selection should occur during feasibility assessment, not after API synthesis or device selection. The downstream implications of choosing the wrong propellant can add 12-18 months to development timelines.

For teams evaluating these options, i2c’s formulation development services provide early-stage compatibility screening that identifies potential formulation challenges before significant resources are committed.

Formulation Challenges in Practice

Challenges with HFO-1234ze

The primary formulation obstacle with HFO-1234ze centres on API solubility optimisation. Whilst reduced solubility benefits suspension stability, it can complicate solution formulation development for APIs requiring dissolved delivery. Our formulation work has identified several practical strategies:

• Co-solvent screening to enhance API solubility whilst maintaining pharmaceutical acceptability
• Excipient selection optimised for HFO-1234ze’s polarity profile
• Particle engineering to achieve optimal aerodynamic properties in suspension formulations
• Valve material compatibility testing to prevent extractables/leachables issues

The lower vapour pressure requires attention to spray pattern characteristics and plume geometry. In our experience, formulation teams often need to iterate valve orifice dimensions and actuator design to achieve equivalent dosing performance to HFC-134a products. This isn’t necessarily disadvantageous—it provides opportunity to optimise patient experience—but it does require appropriate expertise and timeline planning.

Analytical testing becomes particularly critical with HFO-1234ze formulations. Standard methods developed for HFC-134a may require modification to account for different evaporation rates and density effects on cascade impaction results.

Challenges with HFA-152a

The flammability profile represents HFA-152a’s most significant practical challenge. Manufacturing facilities require enhanced safety systems, including explosion-proof equipment, appropriate ventilation, and rigorous process hazard analysis. These requirements increase capital investment and operational complexity compared to non-flammable propellants.

Material compatibility testing must account for HFA-152a’s specific chemical properties. Whilst similarities to HFC-134a exist, assuming complete equivalence can lead to unexpected stability issues or extractables concerns. Comprehensive compatibility programmes should evaluate:

• Elastomer swelling and mechanical property changes
• Valve component extractables under accelerated conditions
• Container material interactions during long-term storage
• Actuator material compatibility across temperature ranges

Regulatory submissions require detailed flammability risk assessments addressing manufacturing, transportation, storage, and patient use scenarios. This documentation burden can extend regulatory timelines compared to HFO-1234ze submissions, though precedents are being established.

For programmes prioritising speed to clinic, our Fast2Clinic service enables rapid formulation iteration whilst maintaining appropriate safety protocols for either propellant option.

Decision Framework: Choosing Your Propellant

The optimal propellant selection depends on project-specific factors that extend beyond simple property comparisons. Consider the following decision criteria:

Choose HFO-1234ze When:

• Environmental sustainability is a regulatory or marketing priority – The near-zero GWP provides maximum future regulatory security
• Your API demonstrates adequate solubility – Or when suspension formulation is appropriate for your therapeutic application
• You’re developing a novel device platform – The opportunity exists to optimise valve and actuator design specifically for HFO-1234ze properties
• Long-term market presence is planned – HFO-1234ze’s environmental profile best positions products for evolving regulations
• Your organisation can invest in formulation optimisation – The potential development complexity is acceptable given sustainability goals

Choose HFA-152a When:

• Reformulation timeline is critical – API solubility similarities to HFC-134a may accelerate development
• Your facility has existing flammability management capabilities – Capital investment in safety systems is already in place
• Device transfer is a priority – The intermediate vapour pressure facilitates minimal valve modifications
• Cost sensitivity is significant – Current market pricing favours HFA-152a, though this may shift
• Regulatory pathway uncertainty is acceptable – Your team can manage potentially extended regulatory dialogue

When Either Option Requires Expert Evaluation:

Many formulation programmes don’t clearly favour one propellant based on these general criteria. In such cases, parallel feasibility studies provide the most reliable decision basis. Early-stage solubility screening, preliminary stability assessment, and device compatibility evaluation with both propellants can be completed within 8-12 weeks, providing empirical data to inform strategic decisions.

i2c’s patented Respitab® technology specifically addresses formulation challenges with both HFO-1234ze and HFA-152a, providing a proven platform for sustainable pMDI development regardless of propellant selection.

Conclusion

The transition from HFC-134a to low-GWP propellants represents more than regulatory compliance—it’s an opportunity to optimise formulation performance whilst addressing environmental concerns. HFO-1234ze and HFA-152a each offer distinct advantages, but neither provides a universal solution. Your optimal choice depends on API properties, device requirements, regulatory strategy, and development timeline constraints.

The formulation complexity inherent in these propellant transitions shouldn’t be underestimated. What appears as straightforward substitution often reveals unexpected solubility, stability, or device compatibility challenges that can derail development programmes. Early engagement with formulation specialists who have practical experience with both propellants provides the technical foundation for confident decision-making.

At i2c, we’ve supported pharmaceutical companies through successful low-GWP propellant transitions for over three decades. Our integrated capabilities—from formulation development through gamma scintigraphy validation—enable comprehensive development programmes under one roof.

Ready to evaluate HFO-1234ze or HFA-152a for your specific formulation? Contact our formulation team for a technical consultation on your API and device requirements, or download our comprehensive whitepaper on low-GWP propellant formulation strategies.

Frequently Asked Questions

Can I simply replace HFC-134a with HFO-1234ze or HFA-152a without reformulation?

No. Whilst some formulation components may transfer directly, the different physical properties—particularly vapour pressure, density, and solvating characteristics—typically require formulation optimisation and device adjustment. Treating low-GWP propellants as drop-in replacements risks stability failures or suboptimal device performance.

Which propellant will regulators prefer?

Regulatory agencies don’t mandate specific propellant selection, but HFO-1234ze’s superior environmental profile (GWP <1) increasingly influences regulatory and reimbursement discussions. HFA-152a remains acceptable but may face enhanced scrutiny regarding flammability management.

How long does propellant transition typically require?

Development timelines vary considerably based on formulation complexity, but expect 18-24 months from propellant selection through clinical batch manufacture for a well-planned programme. Parallel feasibility work and early formulation optimisation can compress timelines significantly.

Are there other low-GWP propellant options beyond these two?

HFO-1234ze and HFA-152a represent the most developed pharmaceutical propellant alternatives currently. Other candidates exist in various research stages, but regulatory pathways and commercial availability remain limited. For programmes requiring near-term market entry, these two options dominate practical consideration.

What compatibility testing is essential before committing to a propellant?

At minimum, conduct API solubility screening, preliminary stability assessment (accelerated conditions), valve component compatibility testing, and spray pattern characterisation. Comprehensive programmes should evaluate extractables/leachables, long-term stability, and moisture sensitivity across the full container-closure system.

Suggested Alt Text for Images:

1. “Molecular structure comparison of HFO-1234ze and HFA-152a propellants showing chemical differences”
2. “Side-by-side comparison chart of vapour pressure, GWP, and density for low-GWP pMDI propellants”
3. “pMDI formulation development workflow showing propellant selection decision points”
4. “Graph showing API solubility profiles in HFO-1234ze versus HFA-152a versus HFC-134a”
5. “i2c Respitab technology diagram illustrating sustainable propellant formulation approach”

Related Content Recommendations for Content Cluster:

• “Navigating HFC Phasedown Regulations: A Timeline for pMDI Developers”
• “How Respitab® Technology Enables Sustainable Inhaler Development”
• “Propellant Compatibility Testing Protocols: What Formulation Teams Need to Know”
• “From HFC-134a to Low-GWP Alternatives: Case Studies in Successful Reformulation”
• “Analytical Method Development for HFO-1234ze Formulations”